CIBC Private Wealth Group
CBIO

CIBC Private Wealth Group’s Crescent Biopharma CBIO Stock Holding History

CIBC Private Wealth Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8
Closed -$13K – 1993
2017
Q4 		$13K Buy
+8
New +$10.6K ﹤0.01% 1488

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIBC Private Wealth Group's CBIO Position: Q1 2018 in Review

CIBC Private Wealth Group sold out of Crescent Biopharma (CBIO) in Q1 2018, closing a stake of 8 shares — an estimated $13K sold.

CIBC Private Wealth Group first reported a position in CBIO in Q4 2017 and held it in 1 quarter. The position peaked at $13K in Q4 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q1 2018.

  • CIBC Private Wealth Group reported no remaining Crescent Biopharma position as of Q1 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 8 Crescent Biopharma shares in Q1 2018, an estimated $13K.
  • CIBC Private Wealth Group first reported a position in Crescent Biopharma in Q4 2017 and held it in 1 quarter.
  • CIBC Private Wealth Group's Crescent Biopharma position peaked at $13K in Q4 2017.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2018.

Based on CIBC Private Wealth Group's 13F filing for Q1 2018, filed 17 May 2018.